A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis With Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Following Hip Fracture Surgery
Latest Information Update: 03 Nov 2021
At a glance
- Drugs TTP 889 (Primary)
- Indications Thromboembolism
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms FIXIT
- Sponsors TransTech Pharma
- 06 Jul 2007 Results have been presented.
- 04 Aug 2006 Status change
- 04 Dec 2005 New trial record.